Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Clozapine has been demonstrated to be useful for treating refractory schizophrenia. However, hypersalivation occurs in 31.0- 97.4% of the patients treated with clozapine. Accordingly, some patients who are disturbed by their hypersalivation refuse to continue with clozapine treatment. This study investigated the efficacy of the anticholinergic agent scopolamine butylbromide against clozapine-induced hypersalivation. Five schizophrenia patients were coadministered scopolamine butylbromide (30-60 mg/ day) for 4 weeks. At the baseline and after 4 weeks’ treatment, we subjectively evaluated hypersalivation using a visual analog scale and objectively assessed it using the Drooling Severity Scale and Drooling Frequency Scale. As a result, improvements in the patients’ Drooling Severity Scale and Drooling Frequency Scale scores, but no improvements in their visual analog scale scores, were observed after scopolamine butylbromide treatment. These results indicate that at least some schizophrenic patients with clozapine-induced hypersalivation would benefit from scopolamine butylbromide treatment. We conclude that clozapine-induced hypersalivation is one factor of stress to patients. Subjective hypersalivation was not improved, but objective hypersalivation was, by scopolamine butylbromide treatment. However, scopolamine butylbromide and clozapine possess anticholinergic effects so clinicians should closely monitor patients who take scopolamine butylbromide.
Abstract
Clozapine has been demonstrated to be useful for treating refractory schizophrenia. However, hypersalivation occurs in 31.0- 97.4% of the patients treated with clozapine. Accordingly, some patients who are disturbed by their hypersalivation refuse to continue with clozapine treatment. This study investigated the efficacy of the anticholinergic agent scopolamine butylbromide against clozapine-induced hypersalivation. Five schizophrenia patients were coadministered scopolamine butylbromide (30-60 mg/ day) for 4 weeks. At the baseline and after 4 weeks’ treatment, we subjectively evaluated hypersalivation using a visual analog scale and objectively assessed it using the Drooling Severity Scale and Drooling Frequency Scale. As a result, improvements in the patients’ Drooling Severity Scale and Drooling Frequency Scale scores, but no improvements in their visual analog scale scores, were observed after scopolamine butylbromide treatment. These results indicate that at least some schizophrenic patients with clozapine-induced hypersalivation would benefit from scopolamine butylbromide treatment. We conclude that clozapine-induced hypersalivation is one factor of stress to patients. Subjective hypersalivation was not improved, but objective hypersalivation was, by scopolamine butylbromide treatment. However, scopolamine butylbromide and clozapine possess anticholinergic effects so clinicians should closely monitor patients who take scopolamine butylbromide.
참고문헌 (17)
- Davydov L., "Clozapine-induced hypersalivation", Ann Pharmacother, 34, pp.662~665 (2000)
- Zeng XP., "Muscarinic m4 receptor activation by some atypical antipsychotic drugs", Eur J Pharmacol, 321, pp.349~354 (1997)
- Kishi T., "Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia : results from a 12-week, flexible dose study using raters masked to antipsychotic choice", Asian J Psychiatr, 6, pp.200~207 (2013)
- Nielsen J., "Psychiatrists' attitude towards and knowledge of clozapine treatment", J Psychopharmacol, 24, pp.965~971 (2010)
- Li Z., "N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors", Neuropsychopharmacology, 30, pp.1986~1995 (2005)
- Zorn SH., "Clozapine is a potent and selective muscarinic M4 receptor agonist", Eur J Pharmacol, 269, pp.R1~R2 (1994)
- McKane JP., "Hyoscine patches in clozapine-induced hypersalivation", Psychiatr Bull, 25, pp.277~ (2001)
- Calderon J., "Potential use of ipatropium bromide for the treatment of clozapine-induced hypersalivation : a preliminary report", Int Clin Psychopharmacol, 15, pp.49~52 (2000)
- Schneider B., "Reduction of clozapine-induced hypersalivation by pirenzepine is safe", Pharmacopsychiatry, 37, pp.43~45 (2004)
- Spivak B., "Trihexyphenidyl treatment of clozapineinduced hypersalivation", Int Clin Psychopharmacol, 12, pp.213~215 (1997)
- Praharaj SK., "Complete resolution of clozapine-induced sialorrhea with low dose trihexyphenidyl", Psychopharmacol Bull, 43, pp.73~75 (2010)
- Leung JG., "Immediate-release oxybutynin for the treatment of clozapine-induced sialorrhea", Ann Pharmacother, 45, pp.e45~ (2011)
- Ancelin ML., "Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs : longitudinal cohort study", BMJ, 332, pp.455~459 (2006)
- Bymaster FP., "Radioreceptor binding profile of the atypical antipsychotic olanzapine", Neuropsychopharmacology, 14, pp.87~96 (1996)
- Tollefson GD., "Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine", Biol Psychiatry, 49, pp.52~63 (2001)
- Weiner DM., "The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine", Psychopharmacology(Berl), 177, pp.207~216 (2004)
- Raufman JP., "Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin", + mice, 2011, pp.32, 1396~1402